Detailed price information for Seastar Medical Hldg Corp (ICU-Q) from The Globe and Mail including charting and trades.

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

The increasing prevalence of kidney failure and end-stage renal disease, along with a growing incidence of risk factors like diabetes, hypertension, and aging, is driving the demand for artificial ...

In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of chronic kidney disease in the US ...

More than half of all men with Klinefelter syndrome (KS) are unaware that they have the condition. Among those who do receive ...

Your health care provider can also see how well blood is flowing in your kidneys. A kidney scan is also called a renal scan or renal scintigraphy. A kidney scan is a type of nuclear imaging test. This ...

The global joint replacement devices market, valued at US$22.50 billion in 2023, is forecasted to grow at a robust CAGR of ...

The global dialysis equipment market is on a strong growth trajectory, with projected sales expected to increase from USD 11,126.0 million in 2024 to an impressive USD 17,780.9 million by 2034. This ...

Some clinical trials have validated a new perspective on continuous renal replacement therapy (CRRT) in combination with oXiris haemofilter to more effectively enhance endotoxins clearance and ...

Semaglutide reduced the risk of kidney disease worsening, renal failure, and CV death by 24% compared ... initiation of chronic kidney replacement therapy (dialysis or kidney transplantation), and ...

Its growth is driven by the rising prevalence of kidney and urological disorders. The global market for nephrology and urology devices is projected to reach $39.3b by 2030, at a compound annual growth ...